Fears of a looming recession seem to be rising, partly fueled by President Donald Trump's macroeconomic policies. While it's ...

Abbott, Dexcom, Insulet, Medtronic and others are developing next-gen sensors, pumps and algorithms for type 2 diabetes ...

Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth. See why we upgraded MDT stock to 'Buy' with a ...

Amsterdam played host to this year's edition of the International Conference on Advanced Technologies & Treatments for ...

Medtronic (NYSE:MDT) today announced real-world data supporting the use of its smart insulin pen and CGM sensor combination.

BD, Medtronic and Abbott were among the top 10 device companies with the highest number of late reports to the FDA, the study ...